🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the fight against drug-resistant strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with figures suggesting in excess of 82 million new cases each year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in concurrent days. This drug, which is employed against UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Results and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses a dual-drug approach. The research involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in many developing nations.

Clinicians treating patients have expressed hope. Having a one-pill regimen like this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to alleviate the strain of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.